Analysts Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Price Target at $20.89

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has received an average rating of “Buy” from the ten ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $20.89.

Several research firms have recently commented on YMAB. HC Wainwright reissued a “buy” rating on shares of Y-mAbs Therapeutics in a research note on Wednesday, December 11th. Oppenheimer assumed coverage on shares of Y-mAbs Therapeutics in a research note on Monday, November 18th. They set an “outperform” rating and a $23.00 price target on the stock. Wedbush reaffirmed an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $20.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday, September 9th. Finally, Brookline Capital Management began coverage on Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $17.00 price objective for the company.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Barclays PLC boosted its stake in shares of Y-mAbs Therapeutics by 433.4% in the third quarter. Barclays PLC now owns 69,222 shares of the company’s stock valued at $910,000 after buying an additional 56,244 shares in the last quarter. Empire Financial Management Company LLC purchased a new stake in shares of Y-mAbs Therapeutics during the 3rd quarter worth $210,000. Geode Capital Management LLC grew its stake in shares of Y-mAbs Therapeutics by 6.2% during the 3rd quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock worth $10,699,000 after purchasing an additional 47,846 shares during the period. State Street Corp increased its holdings in shares of Y-mAbs Therapeutics by 50.4% in the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company’s stock valued at $15,909,000 after purchasing an additional 405,169 shares in the last quarter. Finally, Caligan Partners LP increased its holdings in shares of Y-mAbs Therapeutics by 105.3% in the 3rd quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock valued at $15,718,000 after purchasing an additional 613,175 shares in the last quarter. 70.85% of the stock is currently owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Stock Performance

NASDAQ:YMAB opened at $8.78 on Monday. Y-mAbs Therapeutics has a one year low of $6.09 and a one year high of $20.90. The stock has a market cap of $393.25 million, a PE ratio of -16.26 and a beta of 0.61. The stock has a 50 day moving average price of $12.69 and a 200 day moving average price of $12.65.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The firm had revenue of $18.46 million for the quarter, compared to analyst estimates of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter in the previous year, the business posted ($0.18) earnings per share. As a group, analysts predict that Y-mAbs Therapeutics will post -0.66 earnings per share for the current fiscal year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.